Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.
A clinical trial of epsilon-aminocaproic acid (EACA) in preventing recurrent hemorrhage from intracranial arterial aneurysms is reported. Previous reports were reviewed, and their results concerning antifibrinolytic agents were inconclusive in establishing their efficacy. One hundred patients with documented ruptured intracranial aneurysms were admitted to this study within 48 hours of the initial hemorrhage: 45 patients received 36 gm of EACA/day, with 11 documented rebleeds and one suspected rebleed. No benefit was seen from the use of EACA.
D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications / Q000601:surgery; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D000614:Aminocaproates; D015119:Aminocaproic Acid